SHANGHAI, July 23 /PRNewswire-Asia/ - WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, today announced that Dr. Chi-Chung Chan has been appointed as Vice President of Pharmacology. He will report directly to Dr. Shuhui Chen, Chief Scientific Officer.
Prior to joining WuXi, Dr. Chi-Chung Chan worked at Merck & Co. for 26
years in scientific positions of increasing responsibility. At Merck, he led
pharmacology research efforts in inflammation and pain, allergic diseases,
cardiovascular diseases, respiratory diseases and, most recently, diabetes and
obesity. Dr. Chan obtained a Ph.D. in Pharmacology from the
"I am pleased to welcome Chi-Chung on board as we continue to develop our drug discovery capabilities in pharmacology," said Dr. Ge Li, Chairman and Chief Executive Officer. "WuXi is committed to building a world-class scientific management team with extensive experience in a broad range of scientific disciplines to meet the needs of our customers."
For more information, please contact: Ronald Aldridge (for investors) Director of Investor Relations Tel: +1-201-585-2048 Email: Ron_Aldridge@wuxiapptec.com Stephanie Liu (for the media) Associate Director of Corporate Communications Department Tel: +86-21-5046-4362 Email: email@example.com Web:http://www.wuxiapptec.com
|SOURCE WuXi PharmaTech (Cayman) Inc.|
Copyright©2009 PR Newswire.
All rights reserved